ELENI EFSTATHIOU

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, Giorgi U, Shore ND, Saad F. Plain Language Summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide? Future Oncol. 2023 Aug 10. PMID: 37585665.
      Citations:    Fields:    
    2. Agarwal N, Zhang T, Efstathiou E, Sayegh N, Engelsberg A, Saad F, Fizazi K. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. Eur J Cancer. 2023 10; 192:113249. PMID: 37672815.
      Citations:    Fields:    Translation:Humans
    3. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 Jun 01; 9(6):825-834. PMID: 37022702; PMCID: PMC10080407.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    4. Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S, MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 06 20; 41(18):3339-3351. PMID: 36952634; PMCID: PMC10431499.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    5. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, T?rkeri L, Turco F, Uemura H, Uemura H, ?r?n Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 05; 185:178-215. PMID: 37003085.
      Citations: 3     Fields:    Translation:Humans
    6. Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, De Giorgi U, Shore ND, Saad F. Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial. J Urol. 2023 03; 209(3):532-539. PMID: 36756959.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    7. Riveros C, Ranganathan S, Xu J, Chang C, Kaushik D, Morgan M, Miles BJ, Muhammad T, Anis M, Aghazadeh M, Zhang J, Efstathiou E, Klaassen Z, Brooks MA, Rini B, Wallis CJD, Satkunasivam R. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy. Urol Oncol. 2023 03; 41(3):150.e1-150.e9. PMID: 36610815.
      Citations: 2     Fields:    Translation:Humans
    8. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, T?rkeri L, Turco F, Uemura H, Uemura H, ?r?n Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A, Jereczek-Fossa BA. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023 03; 83(3):267-293. PMID: 36494221; PMCID: PMC7614721.
      Citations: 6     Fields:    Translation:Humans
    9. De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 2022 Oct 13. PMID: 36226865.
      Citations:    
    10. Wallis CJ, Satkunasivam R, Lim K, Teh BS, Guzman J, Zhang J, Farach A, Chen SH, Efstathiou E, Esnaola NF, Sonpavde GP. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial. Future Oncol. 2022 Aug; 18(25):2771-2781. PMID: 35703113.
      Citations:    Fields:    Translation:Humans
    11. Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nat Biotechnol. 2022 11; 40(11):1624-1633. PMID: 35697807; PMCID: PMC9646498.
      Citations:    Fields:    
    12. Dursun F, Lim K, Svatek RS, Xu J, El-Zaatari ZM, Wenker EP, Klaassen ZW, Mansour AM, Muhammad T, Efstathiou E, Sonpavde GP, Wallis CJD, Satkunasivam R. Clinical outcomes and patterns of population-based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database. Cancer Med. 2022 Nov; 11(22):4273-4282. PMID: 35509235; PMCID: PMC9678087.
      Citations:    Fields:    
    13. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A, Bjartell A, Heinrich D, Maluf F, Saad F, T?rkeri L. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):115-141. PMID: 35450732.
      Citations:    Fields:    Translation:Humans
    14. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A, Bjartell A, Fanti S, Heinrich D, Maluf F, Saad F, T?rkeri L. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol. 2022 Jul; 82(1):e18-e19. PMID: 35440417; PMCID: PMC9012951.
      Citations:    Fields:    
    15. Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, Chakraborty G, Wang X, Chen H, Jiang Y, Kumar D, Caggiano EG, Capogiri M, Zhang B, Ji Y, Maity SN, Hu M, Bai S, Aparicio AM, Efstathiou E, Logothetis CJ, Navin N, Navone NM, Chen Y, Giancotti FG. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep. 2022 04 05; 39(1):110595. PMID: 35385726; PMCID: PMC9414743.
      Citations:    Fields:    Translation:HumansAnimalsCells
    16. Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022 04 04; 13(1):1797. PMID: 35379845; PMCID: PMC8980015.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    17. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A, Bjartell A, Fanti S, Heinrich D, Maluf F, Saad F, T?rkeri L. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):6-11. PMID: 35393158; PMCID: PMC8849852.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    18. Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Yu EY, George DJ, Chi KN, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K, GALAHAD investigators, Saad F, St?hl O, Olmos D. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022 03; 23(3):362-373. PMID: 35131040; PMCID: PMC9361481.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    19. Celtik K, Lim K, Dursun F, Xu J, Klaassen Z, Zhang J, Efstathiou E, Sonpavde G, Wallis C, Satkunasivam R. Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National Cancer Database. Clin Genitourin Cancer. 2022 06; 20(3):244-251. PMID: 35181268.
      Citations: 1     Fields:    Translation:Humans
    20. Vogl UM, Beer TM, Davis ID, Shore ND, Sweeney CJ, Ost P, Attard G, Bossi A, de Bono J, Drake CG, Efstathiou E, Fizazi K, Halabi S, James N, Mottet N, Padhani AR, Roach M, Rubin M, Sartor O, Small E, Smith MR, Soule H, Sydes MR, Tombal B, Omlin A, APCCC 2019 expert panel, Fanti S, Gillessen S. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer. 2022 01; 160:24-60. PMID: 34844839.
      Citations:    Fields:    Translation:Humans
    21. De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN, Saad F. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. Eur J Cancer. 2021 12; 159:237-246. PMID: 34784577.
      Citations: 2     Fields:    Translation:Humans
    22. Efstathiou E, Attard G, Flaig TW, Goodman OB, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, Thomas S, Bevans KB, Mundle SD, McCarthy SA, Rathkopf DE, ACIS Investigators, Saad F, Franke F, Oudard S. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021 11; 22(11):1541-1559. PMID: 34600602; PMCID: PMC9377412.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    23. Labanca E, Anselmino N, Yang J, Shepherd PDA, Hoang AG, Tang X, Raso MG, Titus M, Efstathiou E, Araujo J, Logothetis C, Navone N, Bizzotto J, Sanchis P, Paez A, Antico-Arciuch V, Lage-Vickers S, Cotignola J, Vazquez E, Gueron G. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene. 2021 11; 40(44):6284-6298. PMID: 34584218; PMCID: PMC8566229.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    24. Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer. Eur J Cancer. 2021 11; 157:259-267. PMID: 34536949.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    25. Grypari IM, Logotheti S, Zolota V, Troncoso P, Efstathiou E, Bravou V, Melachrinou M, Logothetis C, Tzelepi V. The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. Medicine (Baltimore). 2021 Sep 10; 100(36):e27094. PMID: 34516499; PMCID: PMC8428700.
      Citations: 2     Fields:    Translation:HumansCells
    26. Baiomy A, Martiniova L, Efstathiou E, Schuster DM, Ravizzini G. Prostate Cancer Liver Metastases Presenting as Relatively Photopenic Lesions on 18F-Fluciclovine PET/CT. Clin Nucl Med. 2021 Apr 01; 46(4):e240-e241. PMID: 33208612.
      Citations:    Fields:    Translation:Humans
    27. Wu WF, Wang L, Spetsieris N, Boukovala M, Efstathiou E, Warner M, Gustafsson JA, Br?ssner C. Estrogen receptor ? and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate. Proc Natl Acad Sci U S A. 2021 03 30; 118(13). PMID: 33771918; PMCID: PMC8020780.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    28. Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh N, Guerra L, Lee YC, Lin SC, Yu G, Santos E, Melancon MP, Troncoso P, Navone N, Gallick GE, Efstathiou E, Subudhi SK, Lin SH, Logothetis CJ, Panaretakis T. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res. 2021 06 01; 27(11):3253-3264. PMID: 33753455; PMCID: PMC8172463.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    29. Spetsieris N, Boukovala M, Patsakis G, Alafis I, Efstathiou E. Neuroendocrine and Aggressive-Variant Prostate Cancer. Cancers (Basel). 2020 Dec 16; 12(12). PMID: 33339136; PMCID: PMC7765615.
      Citations: 8     
    30. Saad F, Sternberg CN, Efstathiou E, Fizazi K, Modelska K, Lin X, Sugg J, Steinberg J, Shore ND, Hussain M, Noerby B. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. Eur Urol. 2020 12; 78(6):847-853. PMID: 33010985.
      Citations:    Fields:    Translation:Humans
    31. Delanoy N, Hardy-Bessard AC, Efstathiou E, Moulec SL, Basso U, Birtle A, Thomson A, Krainer M, Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Butt M, Priou F, Lechevallier E, Deville JL, Gross-Goupil M, Morales R, Gavrikova T, Sella A, Fizazi K, Ferrero JM, Thibault C, Hans S, Guillot A, Fl?chon A, Alexandre J, Helissey C, Thiery-Vuillemin A, Barth?l?my P, Laguerre B, Oudard S. Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163]. Eur J Cancer. 2020 Sep; 137:290-291. PMID: 32723589.
      Citations:    Fields:    
    32. Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Butt M, Priou F, Lechevallier E, Deville JL, Gross-Goupil M, Morales R, Gavrikova T, Sella A, Fizazi K, Ferrero JM, Thibault C, Hans S, Guillot A, Fl?chon A, Alexandre J, Helissey C, Thiery-Vuillemin A, Barth?l?my P, Laguerre B, Oudard S. Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163]. Eur J Cancer. 2020 Sep; 137:288-289. PMID: 32605716.
      Citations:    Fields:    
    33. Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020 09 15; 26(18):4933-4946. PMID: 32576626; PMCID: PMC7501166.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    34. Boukovala M, Spetsieris N, Efstathiou E. An evaluation of apalutamide for the treatment of prostate cancer. Expert Opin Pharmacother. 2020 Sep; 21(13):1537-1546. PMID: 32543237.
      Citations: 2     Fields:    Translation:HumansAnimals
    35. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5. PMID: 32675015; PMCID: PMC10014037.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    36. PROSPER Investigators, Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020 06 04; 382(23):2197-2206. PMID: 32469184.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    37. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, van Oort I, Zapatero A, Omlin A, Bjartell A, Fanti S, Heinrich D, Maluf F, Saad F, T?rkeri L. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547. PMID: 32001144.
      Citations: 91     Fields:    Translation:Humans
    38. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75. PMID: 31986451; PMCID: PMC7350510.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    39. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999. PMID: 31941830.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    40. Tzelepi V, Logotheti S, Efstathiou E, Troncoso P, Aparicio A, Sakellakis M, Hoang A, Perimenis P, Melachrinou M, Logothetis C, Zolota V. Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression. Pathology. 2020 Feb; 52(2):218-227. PMID: 31864524.
      Citations: 10     Fields:    Translation:HumansCells
    41. Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Butt M, Priou F, Lechevallier E, Deville JL, Gross-Goupil M, Morales R, Gavrikova T, Sella A, Fizazi K, Ferrero JM, Thibault C, Hans S, Guillot A, Fl?chon A, Alexandre J, Helissey C, Thiery-Vuillemin A, Barth?l?my P, Laguerre B, Oudard S. Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. Eur J Cancer. 2020 01; 125:153-163. PMID: 31787484.
      Citations: 2     Fields:    Translation:Humans
    42. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019 10; 20(10):1432-1443. PMID: 31515154; PMCID: PMC6858999.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    43. Boukovala M, Spetsieris N, Efstathiou E. Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies. Drugs Aging. 2019 08; 36(8):701-717. PMID: 31172421.
      Citations: 5     Fields:    Translation:Humans
    44. Logothetis CJ, Aparicio A, Koinis F, Corn PG, Efstathiou E. Prostate Cancer: Quo Vadis? Eur Urol. 2019 Dec; 76(6):709-711. PMID: 31300238.
      Citations: 1     Fields:    Translation:Humans
    45. Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, Gormley M, Ricci D, Titus M, Hoang A, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Troncoso P, Logothetis CJ. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. Eur Urol. 2019 10; 76(4):418-424. PMID: 31176622; PMCID: PMC7205516.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    46. Del Re M, Crucitta S, Sbrana A, Rofi E, Paolieri F, Gianfilippo G, Galli L, Falcone A, Morganti R, Porta C, Efstathiou E, van Schaik R, Jenster G, Danesi R. AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer. BJU Int. 2019 May 04. PMID: 31055861.
      Citations: 15     Fields:    
    47. Efstathiou E, Titus M, Wen S, Troncoso P, Hoang A, Corn P, Prokhorova I, Araujo J, Dmuchowski C, Melhem-Bertrandt A, Patil S, Logothetis CJ. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Oncol. 2020 02; 3(1):119-127. PMID: 31412017; PMCID: PMC7204265.
      Citations: 8     Fields:    Translation:Humans
    48. Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres-Cabala CA, Efstathiou E, Hoang AG, Wong MK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba I, Tetzlaff MT. B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clin Cancer Res. 2019 06 01; 25(11):3455-3467. PMID: 30808776; PMCID: PMC8211110.
      Citations: 9     Fields:    Translation:HumansCells
    49. Zacharias N, Lee J, Ramachandran S, Shanmugavelandy S, McHenry J, Dutta P, Millward S, Gammon S, Efstathiou E, Troncoso P, Frigo DE, Piwnica-Worms D, Logothetis CJ, Maity SN, Titus MA, Bhattacharya P. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol. 2019 02; 21(1):86-94. PMID: 29748904; PMCID: PMC6230314.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    50. Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E, Santer FR. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate. 2018 12; 78(16):1262-1282. PMID: 30073676.
      Citations: 33     Fields:    Translation:HumansAnimals
    51. Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Butt M, Priou F, Deville JL, Goupil MG, Morales R, Gavrikova T, Sella A, Fizazi K, Baciarello G, Fererro JM, Verret B, Hans S, Guillot A, Fl?chon A, Alexandre J, Helissey C, Lechevallier ?, Thiery-Vuillemin A, Barthelemy P, Laguerre B, Oudard S. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. Eur Urol Oncol. 2018 12; 1(6):467-475. PMID: 31158090.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    52. Efstathiou E. The case for 'successfully' treating hormone na?ve metastatic prostate cancer. Ann Oncol. 2018 05 01; 29(5):1084-1086. PMID: 29688267.
      Citations:    Fields:    Translation:Humans
    53. Angelergues A, Efstathiou E, Gyftaki R, Wysocki PJ, Lainez N, Gonzalez I, Castellano DE, Ozguroglu M, Carbonero IG, Balea BC, Esteban E, Rubio G, Birtle AJ, Delanoy N, Bellmunt J, Flechon A, Borrega P, Guillot A, Le Moulec S, Munarriz J, Oudard S. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents. Clin Genitourin Cancer. 2018 08; 16(4):e777-e784. PMID: 29550200.
      Citations: 6     Fields:    Translation:Humans
    54. Ryan CJ, Kheoh T, Li J, Molina A, De Porre P, Carles J, Efstathiou E, Kantoff PW, Mulders PFA, Chi KN, Saad F. Prognostic Index Model for Progression-Free Survival in Chemotherapy-Na?ve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. Clin Genitourin Cancer. 2017 Jul 25. PMID: 28844792; PMCID: PMC5785489.
      Citations: 11     Fields:    
    55. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Drake CG, Eeles R, Efstathiou E, Evans CP, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Omlin A, Borges Dos Reis R, Fanti S, Heidenreich A, Maluf F, Saad F, Valdagni R, Wiegel T. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211. PMID: 28655541.
      Citations: 162     Fields:    Translation:Humans
    56. Efstathiou E. Attaining precision therapy in prostate cancer: A tall order. Eur J Cancer. 2017 08; 81:226-227. PMID: 28629596; PMCID: PMC6051349.
      Citations:    Fields:    Translation:HumansCells
    57. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555. PMID: 28346412; PMCID: PMC5466900.
      Citations: 199     Fields:    Translation:HumansAnimalsCells
    58. Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Soghomonyan S, Alauddin MM, Flores LG, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Gelovani JG, Sidman RL, Pasqualini R, Arap W, Card?-Vila M, Arap MA, Marchi? S. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci U S A. 2016 Nov 08; 113(45):12786-12791. PMID: 27791181; PMCID: PMC5111687.
      Citations: 21     Fields:    
    59. Maity SN, Titus MA, Gyftaki R, Wu G, Lu JF, Ramachandran S, Li-Ning-Tapia EM, Logothetis CJ, Araujo JC, Efstathiou E. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Sci Rep. 2016 10 17; 6:35354. PMID: 27748439; PMCID: PMC5066251.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    60. Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 2016 Jul 19; 7(29):46321-46334. PMID: 27331874; PMCID: PMC5216801.
      Citations: 9     Fields:    Translation:HumansAnimals
    61. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93. PMID: 27322462; PMCID: PMC4909608.
      Citations: 2     Fields:    Translation:Humans
    62. Efstathiou E, Soo Kim C, Horchani A, Hitier S, ?zen H, Droz JP, Yildirim A, Cabrera P, Heidenreich A, Rinck-Junior JA. First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry. Urol Oncol. 2016 May; 34(5):234.e21-9. PMID: 26777260.
      Citations: 4     Fields:    Translation:Humans
    63. Drivalos A, Chrisofos M, Efstathiou E, Kapranou A, Kollaitis G, Koutlis G, Antoniou N, Karanastasis D, Dimopoulos MA, Bamias A. Expression of a5-integrin, a7-integrin, ?-cadherin, and N-cadherin in localized prostate cancer. Urol Oncol. 2016 Apr; 34(4):165.e11-8. PMID: 26652134.
      Citations: 13     Fields:    Translation:Humans
    64. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):107-21. PMID: 26272062; PMCID: PMC4703437.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    65. Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. Eur Urol. 2015 Nov; 68(5):850-8. PMID: 26153564.
      Citations: 26     Fields:    Translation:Humans
    66. Salameh A, Lee AK, Efstathiou E, Staquicini FI, Dobroff AS, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Calin GA, Cavenee WK, Pasqualini R, Arap W, Card?-Vila M, Nunes DN, Marchi? S, Lima LA, Carraro DM, Brentani RR, Dias-Neto E. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8403-8. PMID: 26080435; PMCID: PMC4500257.
      Citations: 99     Fields:    Translation:HumansAnimalsCells
    67. Pasqualini R, Millikan RE, Christianson DR, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W, Card?-Vila M. Targeting the interleukin-11 receptor a in metastatic prostate cancer: A first-in-man study. Cancer. 2015 Jul 15; 121(14):2411-21. PMID: 25832466; PMCID: PMC4490036.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    68. Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R, ELM-PC 4 investigators, Saad F. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015 Mar; 16(3):338-48. PMID: 25701170.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    69. Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, Scher HI. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. Eur Urol. 2015 Nov; 68(5):795-801. PMID: 25698064; PMCID: PMC5013546.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    70. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015 Mar 01; 33(7):723-31. PMID: 25624429; PMCID: PMC4879718.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    71. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 03; 6(252):252ra122. PMID: 25186177; PMCID: PMC4407499.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    72. Aapro M, Balducci L, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou E, Emberton M, Fitzpatrick JM, Heidenreich A, Hughes S, Joniau S, Kattan M, Mottet N, Payne H, Sugihara T, Droz JP, Boyle H, Oudard S, Saad F. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014 Aug; 15(9):e404-14. PMID: 25079103.
      Citations: 59     Fields:    Translation:Humans
    73. Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol. 2015 May; 67(5):866-73. PMID: 25018037.
      Citations: 18     Fields:    Translation:Humans
    74. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67(1):53-60. PMID: 24882673; PMCID: PMC4247811.
      Citations: 96     Fields:    Translation:HumansCellsCTClinical Trials
    75. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal. 2014 May 20; 7(326):ra47. PMID: 24847116; PMCID: PMC4135429.
      Citations: 47     Fields:    Translation:HumansAnimals
    76. Wilton JH, Titus MA, Efstathiou E, Fetterly GJ, Mohler JL. Androgenic biomarker prof|ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate. 2014 May; 74(7):722-31. PMID: 24847527; PMCID: PMC4335642.
      Citations: 9     Fields:    Translation:Humans
    77. Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Gillessen S, Kellokumpu-Lehtinen PL, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R, Tombal B, Foss? S, Lecouvet FE. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer. 2014 Jun; 50(9):1617-27. PMID: 24703899.
      Citations: 50     Fields:    Translation:Humans
    78. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Van Poppel H, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Fradet Y, Carles J, Saad F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25. PMID: 24647231; PMCID: PMC4418928.
      Citations: 86     Fields:    Translation:HumansCTClinical Trials
    79. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013 Dec 05; 155(6):1309-22. PMID: 24315100; PMCID: PMC3932525.
      Citations: 410     Fields:    Translation:HumansAnimalsCells
    80. Araujo JC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ, Trudel GC. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1307-16. PMID: 24211163; PMCID: PMC5478530.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    81. Som A, Xiao L, Zhu R, Guo CC, Xiao L, Rao P, Efstathiou E, Matin A, Tu SM. Clinically atypical seminomas with yolk sac tumor features. Can J Urol. 2013 Aug; 20(4):6860-7. PMID: 23930614.
      Citations: 1     Fields:    Translation:Humans
    82. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013 Aug; 3(8):849-61. PMID: 23811619; PMCID: PMC3926428.
      Citations: 66     Fields:    Translation:Humans
    83. Mourmouris P, Efstathiou E, Papatsoris A. Androgen deprivation therapy and cardiovascular risk. Nephrourol Mon. 2013; 5(1):653-4. PMID: 23577326; PMCID: PMC3614327.
      Citations: 2     
    84. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48. PMID: 23228172; PMCID: PMC3683570.
      Citations: 869     Fields:    Translation:Humans
    85. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012 Dec; 13(12):1210-7. PMID: 23142059.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    86. Dimopoulos S, Eleftherakis E, Charitos C, Sakellaridis T, Sinapidis D, Kostis E, Toumanidis S, Efstathiou E. Bartonella quintana endocarditis as a cause of severe aortic insufficiency and heart failure. Hellenic J Cardiol. 2012 Nov-Dec; 53(6):476-9. PMID: 23178432.
      Citations:    Fields:    Translation:Humans
    87. Efstathiou E, Karlou M, Wen S, Hoang A, Pettaway CA, Pisters LL, Maity S, Troncoso P, Logothetis CJ. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate. 2013 Jan; 73(2):153-61. PMID: 22753310; PMCID: PMC3878994.
      Citations: 12     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    88. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate. 2012 Nov; 72(15):1638-47. PMID: 22457212; PMCID: PMC4977841.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    89. Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone N, Troncoso P, Zhang W. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One. 2012; 7(2):e31259. PMID: 22363599; PMCID: PMC3281954.
      Citations: 4     Fields:    Translation:HumansCells
    90. Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM. Activation of ?-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res. 2012 Feb 01; 18(3):726-36. PMID: 22298898; PMCID: PMC3271798.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    91. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W, Koumakpayi IH. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol. 2012 Mar; 180(3):895-903. PMID: 22245216; PMCID: PMC4715215.
      Citations: 37     Fields:    Translation:AnimalsCells
    92. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. 2012 Feb 20; 30(6):637-43. PMID: 22184395; PMCID: PMC3295561.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    93. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012 Feb 01; 18(3):666-77. PMID: 22156612; PMCID: PMC3923417.
      Citations: 70     Fields:    Translation:HumansAnimals
    94. Staquicini FI, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W, Card?-Vila M, Setubal JC. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18637-42. PMID: 22049339; PMCID: PMC3219136.
      Citations: 42     Fields:    Translation:HumansCells
    95. Logothetis CJ, Efstathiou E, Manuguid F, Kirkpatrick P. Abiraterone acetate. Nat Rev Drug Discov. 2011 Aug 01; 10(8):573-4. PMID: 21804589.
      Citations: 6     Fields:    Translation:Humans
    96. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61. PMID: 21632851; PMCID: PMC3657705.
      Citations: 93     Fields:    Translation:HumansCTClinical Trials
    97. Tzelepi V, Karlou M, Wen S, Hoang A, Logothetis C, Troncoso P, Efstathiou E. Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology. 2011 Jun; 58(7):1037-47. PMID: 21707705; PMCID: PMC4934422.
      Citations: 24     Fields:    Translation:Humans
    98. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators, Fl?chon A. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26; 364(21):1995-2005. PMID: 21612468; PMCID: PMC3471149.
      Citations: 1619     Fields:    Translation:HumansCTClinical Trials
    99. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011 Jun 20; 29(18):2574-81. PMID: 21606419; PMCID: PMC3138635.
      Citations: 26     Fields:    Translation:HumansCellsCTClinical Trials
    100. Drivalos A, Papatsoris AG, Chrisofos M, Efstathiou E, Dimopoulos MA. The role of the cell adhesion molecules (integrins/cadherins) in prostate cancer. Int Braz J Urol. 2011 May-Jun; 37(3):302-6. PMID: 21756376.
      Citations: 5     Fields:    Translation:Humans
    101. Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Bamias A, Dimopoulos MA. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res. 2011 Apr; 31(4):1475-82. PMID: 21508406.
      Citations: 9     Fields:    Translation:Humans
    102. Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A, Tsiatas M, Papadimitriou C, Bamias A, Dimopoulos MA. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology. 2011 Mar; 77(3):682-7. PMID: 21256546.
      Citations: 10     Fields:    Translation:Humans
    103. Bourdoumis A, Papatsoris AG, Chrisofos M, Efstathiou E, Skolarikos A, Deliveliotis C. The novel prostate cancer antigen 3 (PCA3) biomarker. Int Braz J Urol. 2010 Nov-Dec; 36(6):665-8; discussion 669. PMID: 21176272.
      Citations: 6     Fields:    Translation:Humans
    104. Eleutherakis-Papaiakovou E, Kostis E, Migkou M, Christoulas D, Terpos E, Gavriatopoulou M, Roussou M, Bournakis E, Kastritis E, Efstathiou E, Dimopoulos MA, Papadimitriou CA. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol. 2010 Nov; 85(11):863-7. PMID: 20882526.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    105. Som A, Zhu R, Guo CC, Efstathiou E, Xiao L, Pisters LL, Matin A, Tu SM. Recurrent seminomas: clinical features and biologic implications. Urol Oncol. 2012 Jul-Aug; 30(4):494-501. PMID: 20822932; PMCID: PMC3856193.
      Citations: 4     Fields:    Translation:Humans
    106. Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol. 2010 Sep; 7(9):494-509. PMID: 20818327.
      Citations: 54     Fields:    Translation:HumansCells
    107. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24; 375(9724):1437-46. PMID: 20398925; PMCID: PMC2948179.
      Citations: 445     Fields:    Translation:HumansCTClinical Trials
    108. Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol. 2010 Jul; 85(1):1-5. PMID: 20192988.
      Citations: 19     Fields:    Translation:Humans
    109. Efstathiou E, Logothetis CJ. A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res. 2010 Feb 15; 16(4):1100-7. PMID: 20145177; PMCID: PMC3891669.
      Citations: 17     Fields:    Translation:Humans
    110. Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol. 2010 Jun; 57(6):1030-8. PMID: 19853370; PMCID: PMC2962710.
      Citations: 20     Fields:    Translation:Humans
    111. Efstathiou E, Kim J, Logothetis CJ. Informative clinical investigation: a demanding taskmaster. J Clin Oncol. 2009 Oct 20; 27(30):4937-8. PMID: 19720892.
      Citations: 1     Fields:    Translation:Humans
    112. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics. 2009 Aug 04; 2:48. PMID: 19653896; PMCID: PMC2731785.
      Citations: 26     Fields:    
    113. Efstathiou E, Logothetis CJ. Prostate cancer: thalidomide for prostate cancer: is there progress? Nat Rev Urol. 2009 May; 6(5):248-50. PMID: 19424170.
      Citations:    Fields:    Translation:Humans
    114. Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, Dimopoulos MA. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opin Biol Ther. 2009 Apr; 9(4):465-79. PMID: 19344283.
      Citations: 9     Fields:    Translation:HumansAnimals
    115. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20. PMID: 19244175; PMCID: PMC2734116.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    116. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther. 2008 Oct; 7(10):1619-27. PMID: 19018165.
      Citations: 7     Fields:    Translation:Humans
    117. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008 Aug; 118(8):2697-710. PMID: 18618013; PMCID: PMC2447924.
      Citations: 105     Fields:    Translation:HumansAnimalsCells
    118. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1224-31. PMID: 17317833.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    119. Efstathiou E, Dimopoulos MA, Bozas G, Kastritis E, Moulopoulos LA, Rodolakis A, Vlahos G, Gika D, Papadimitriou C, Bamias A. Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res. 2007 Jan-Feb; 27(1B):611-7. PMID: 17348450.
      Citations: 4     Fields:    Translation:HumansCells
    120. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw. 2006 Nov; 4(10):1059-70. PMID: 17112453.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    121. Bozas G, Bamias A, Koutsoukou V, Efstathiou E, Gika D, Papadimitriou CA, Dimopoulos MA. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol. 2007 Mar; 104(3):580-5. PMID: 17052747.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    122. Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D, Dimopoulos MA. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer. 2006 Sep 25; 6:228. PMID: 16999858; PMCID: PMC1592509.
      Citations: 1     Fields:    Translation:Humans
    123. Bozas G, Dimopoulos MA, Kastritis E, Efstathiou E, Koutsoukou V, Rodolakis A, Vlahos G, Voulgaris Z, Papageorgiou T, Gika D, Papadimitriou C, Bamias A. Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology. 2006; 70(4):265-72. PMID: 16899981.
      Citations: 5     Fields:    Translation:Humans
    124. Psyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S, Kowalski D, Efstathiou E, Camp RL, Rimm DL, Dimopoulos MA. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res. 2005 Dec 01; 11(23):8384-90. PMID: 16322299.
      Citations: 12     Fields:    Translation:HumansCells
    125. Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA. Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res. 2005 Sep-Oct; 25(5):3553-8. PMID: 16101179.
      Citations: 21     Fields:    Translation:Humans
    126. Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, Papadimitriou C, Dimopoulos MA. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer. 2005 Jun 15; 103(12):2629-35. PMID: 15856427.
      Citations: 12     Fields:    Translation:Humans
    127. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, Dimopoulos MA. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005 May; 97(2):436-41. PMID: 15863142.
      Citations: 36     Fields:    Translation:Humans
    128. Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, Kalofonos H, Kouroussis C, Gika D, Skarlos D, Bamias A. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol. 2004 Dec; 95(3):695-700. PMID: 15581984.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    129. Linardou H, Aravantinos G, Efstathiou E, Kalofonos C, Anagnostopoulos A, Deliveliotis C, Bafaloukos D, Athanasios Dimopoulos M, Bamias A, Phase II study of Hellenic Co-operative Oncology Group. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology. 2004 Sep; 64(3):479-84. PMID: 15351574.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    130. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, Poziopoulos C, Xilouri I, Zorzou MP, Anagnostopoulos N, Anagnostopoulos A. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004; 5(2):112-7. PMID: 15048060.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    131. Zorzou MP, Stratigos A, Efstathiou E, Bamias A. Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. Acta Derm Venereol. 2004; 84(4):308-9. PMID: 15339078.
      Citations: 11     Fields:    Translation:Humans
    132. Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, Hamilos G, Zorzou M, Dimopoulos MA. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology. 2004; 66(2):112-7. PMID: 15138362.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    133. Dimopoulos MA, Hamilos G, Efstathiou E, Siapkaras I, Matsouka C, Gika D, Grigoraki V, Papadimitriou C, Mitsibounas D, Anagnostopoulos N. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma. 2003 Jun; 44(6):993-6. PMID: 12854900.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    134. Kroupis C, Lianidou E, Goutas N, Ladopoulou A, Konstantopoulou I, Pantazidis A, Yannoukakos D, Efstathiou E, Vourlidis N, Tsionou C. Atypical medullary breast carcinoma in a family carrying the 5382insC BRCA-1 mutation. Breast J. 2003 May-Jun; 9(3):260-2. PMID: 12752644.
      Citations: 2     Fields:    Translation:Humans
    135. Dimopoulos MA, Zervas C, Zomas A, Hamilos G, Gika D, Efstathiou E, Panayiotidis P, Vervessou E, Anagnostopoulos N, Christakis J. Extended rituximab therapy for previously untreated patients with Waldenstr?m's macroglobulinemia. Clin Lymphoma. 2002 Dec; 3(3):163-6. PMID: 12521393.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    136. Ladopoulou A, Konstantopoulou I, Armaou S, Efstathiou E, Mihalatos M, Nasioulas G, Bardi G, Pandis N, Yannoukakos D, Hellenic Cooperative Oncology Group. A change in the last base of BRCA1 exon 23, 5586G-->A, results in abnormal RNA splicing. Cancer Genet Cytogenet. 2002 Apr 15; 134(2):175-7. PMID: 12034536.
      Citations: 1     Fields:    Translation:HumansCells
    137. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine.
    138. Clinically atypical seminomas with yolk sac tumor features. Canadian Journal of Urology. 20:6860-6867.
    139. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European Urology. 66:815-825.
    140. First-line treatment in senior adults with metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations.
    141. Integrating murine and clinical trials with cabozantinib to understand roles of MET and VEGFR2 as targets for growth inhibition of prostate cancer. Clinical Cancer Research. 22:107-121.
    142. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Scientific Reports. 6.
    143. Targeted molecular-genetic imaging and liganddirected therapy in aggressive variant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 113:12786-12791.
    144. Clinical trials in oncology. Forum of Clinical Oncology. 3:9-13.
    145. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 7:46321-46334.
    146. Erratum. Science Translational Medicine. 7.
    147. Management of patients with advanced prostate cancer. Annals of Oncology. 26:1589-1604.
    148. Clinical Challenges for Treatment and a Cure. 155-167.
    149. Urologic Oncology: Seminars and Original Investigations. 34:165.e11-165.e18.
    EFSTATHIOU's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (501)
    Explore
    _
    Co-Authors (91)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _